Difference between revisions of "Tranylcypromine-fluoxetine"
From Psychiatrienet
| Line 8: | Line 8: | ||
* ''' After 3 weeks:''' If necessary, gradually increase dosage of fluoxetine.<ref name="informatorium">{{KNMP|tranylcypromine}}</ref> | * ''' After 3 weeks:''' If necessary, gradually increase dosage of fluoxetine.<ref name="informatorium">{{KNMP|tranylcypromine}}</ref> | ||
| info = | | info = | ||
| − | |||
{{Tcwashout}} | {{Tcwashout}} | ||
{{Tcrestore}}<ref name="informatorium">{{KNMP|tranylcypromine}}</ref> | {{Tcrestore}}<ref name="informatorium">{{KNMP|tranylcypromine}}</ref> | ||
Revision as of 14:16, 8 March 2024
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from tranylcypromine to fluoxetine.[1] [2]
Stop tranylcypromine - Day 1: decrease the original dose with about 25% every 3 days.
- Day 9: stop administration of tranylcypromine.
Start fluoxetine- Day 6 and after: At approximately 50-25% of the original TCA dosering start fluoxetine at 100% of the target dose.
- After 3 weeks: If necessary, gradually increase dosage of fluoxetine.[3]
More information- Occurrence of the serotonin syndrome is possible without this wash-out period.
- After the last dose of tranylcypromine it takes about 14 days to restore the activity of the MAO enzymes[3]
- Tranylcypromine has to be phased out to avoid withdrawal symptoms.[4]
- Plasma monitoring for TCA's is advisable, because of plasma-reponse relations, genetic polymorphism and under or overdosing.[5]
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ 3.0 3.1 KNMP; Informatorium Medicamentorum 2023; Monografie "tranylcypromine" (Dutch)
- ↑ Dr. M.J.Blom et al. (2009) Gebruik van klassieke MAO-remmers
- ↑ (dutch) monografie.org tricyclische-antidepressiva
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
